Recently, the immunotherapy represented by immune-checkpoint blockade(ICB) has achieved prominent efficacy in the treatment of cancers. However, the lack of efficient biomarkers has limited the clinical application of ICB to a large extent. Genetic mutations in tumor cells can be recognized by mature T cells as neoantigens, and thus induce neoantigen specific T cell response and anti-tumor immune response. With the development of DNA sequencing, the detection of tumor mutational burden(TMB) has become a com...
| 
推荐 
点击下列相关研究机构和相关文献作者，可以直接查到这些机构和作者被《中国知识资源总库》收录的其它文献，使您全面了解该机构和该作者的研究动态和历史。
